CRISPR Therapeutics (NASDAQ:CRSP) Given “Sector Perform” Rating at Royal Bank of Canada

Royal Bank of Canada reaffirmed their sector perform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report issued on Wednesday, Benzinga reports. Royal Bank of Canada currently has a $53.00 price target on the stock.

CRSP has been the topic of a number of other reports. Stifel Nicolaus dropped their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Rodman & Renshaw started coverage on CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price for the company. Chardan Capital dropped their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Tuesday, October 29th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $51.15 on Wednesday. The company has a market cap of $4.35 billion, a P/E ratio of -15.70 and a beta of 1.67. The business’s 50 day moving average price is $47.29 and its 200-day moving average price is $52.24. CRISPR Therapeutics has a fifty-two week low of $43.42 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the company posted ($1.41) earnings per share. As a group, equities analysts predict that CRISPR Therapeutics will post -5.57 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Global Trust Asset Management LLC lifted its holdings in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC lifted its stake in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the period. GPS Wealth Strategies Group LLC lifted its stake in shares of CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics during the second quarter valued at $35,000. Finally, Denver PWM LLC acquired a new stake in CRISPR Therapeutics during the second quarter valued at $45,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.